{"id":1768,"date":"2016-06-29T16:04:44","date_gmt":"2016-06-29T20:04:44","guid":{"rendered":"http:\/\/groupedevonian.com\/en\/fr\/?page_id=1768"},"modified":"2026-05-14T10:01:59","modified_gmt":"2026-05-14T14:01:59","slug":"therapeutic","status":"publish","type":"page","link":"https:\/\/groupedevonian.com\/fr\/produits\/therapeutic\/","title":{"rendered":"Produits th\u00e9rapeutiques"},"content":{"rendered":"<p>[et_pb_section fb_built=\u00a0\u00bb1&Prime; _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_padding=\u00a0\u00bb100px||100px||true|\u00a0\u00bb top_divider_color=\u00a0\u00bb#1B303B\u00a0\u00bb top_divider_height=\u00a0\u00bb50px\u00a0\u00bb bottom_divider_color=\u00a0\u00bb#1B303B\u00a0\u00bb bottom_divider_height=\u00a0\u00bb50px\u00a0\u00bb bottom_divider_flip=\u00a0\u00bbhorizontal\u00a0\u00bb custom_css_main_element=\u00a0\u00bbbackground: url(\/wp-content\/uploads\/2025\/11\/dots-br.png)\/*, url(\/wp-content\/uploads\/2025\/11\/lines-bl.png)*\/, url(\/wp-content\/uploads\/2025\/11\/dots-tl.png)\/*, url(\/wp-content\/uploads\/2025\/11\/lueur-bl-v2.png)*\/ !important;||background-repeat: no-repeat !important;||background-position: right bottom,\/* left bottom,*\/ left top\/*, left bottom*\/  !important;||background-size: auto !important;\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb custom_css_main_element_last_edited=\u00a0\u00bbon|desktop\u00a0\u00bb custom_css_main_element_tablet=\u00a0\u00bbbackground: url(\/wp-content\/uploads\/2025\/11\/dots-br.png)\/*, url(\/wp-content\/uploads\/2025\/11\/lines-bl.png)*\/, url(\/wp-content\/uploads\/2025\/12\/dot-top-right.png)\/*, url(\/wp-content\/uploads\/2025\/11\/lueur-bl-v2.png)*\/ !important;||background-repeat: no-repeat !important;||background-position: right bottom\/*, left bottom*\/, right top\/*, left bottom *\/ !important;||background-size: auto !important;\u00a0\u00bb custom_css_main_element_phone=\u00a0\u00bbbackground: url(\/wp-content\/uploads\/2025\/11\/dots-br.png)\/*, url(\/wp-content\/uploads\/2025\/11\/lines-bl.png)*\/, url(\/wp-content\/uploads\/2025\/12\/dot-top-right.png)\/*, url(\/wp-content\/uploads\/2025\/11\/lueur-bl-v2.png)*\/ !important;||background-repeat: no-repeat !important;||background-position: right bottom\/*, left bottom*\/, right top\/*, left bottom *\/ !important;||background-size: auto !important;\u00a0\u00bb][et_pb_row custom_padding_last_edited=\u00a0\u00bbon|tablet\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_enable_image=\u00a0\u00bboff\u00a0\u00bb background_size=\u00a0\u00bbcontain\u00a0\u00bb background_blend=\u00a0\u00bbsoft-light\u00a0\u00bb max_width=\u00a0\u00bb80%\u00a0\u00bb custom_margin_tablet=\u00a0\u00bb0px||||false|false\u00a0\u00bb custom_margin_phone=\u00a0\u00bb0px||||false|false\u00a0\u00bb custom_margin_last_edited=\u00a0\u00bbon|tablet\u00a0\u00bb custom_padding_tablet=\u00a0\u00bb0px||||false|false\u00a0\u00bb custom_padding_phone=\u00a0\u00bb0px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text admin_label=\u00a0\u00bbTherapeutics\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.5&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_text_color=\u00a0\u00bb#1F386B\u00a0\u00bb header_2_font_size=\u00a0\u00bb36px\u00a0\u00bb background_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h1><strong>Produits th\u00e9rapeutiques<\/strong><\/h1>\n<p>[\/et_pb_text][et_pb_text admin_label=\u00a0\u00bbThykamineTM\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_text_color=\u00a0\u00bb#1F386B\u00a0\u00bb width=\u00a0\u00bb100%\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb custom_margin=\u00a0\u00bb|0px|||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb|0px|||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h2>Thykamine<sup>MC<\/sup><\/h2>\n<p><\/p>\n<p>Thykamine<sup>MC<\/sup>\u00a0constitue un candidat-m\u00e9dicament de premier plan dont les profils d\u2019innocuit\u00e9 et d\u2019efficacit\u00e9 ont \u00e9t\u00e9 d\u00e9montr\u00e9s dans de nombreuses \u00e9tudes pr\u00e9cliniques et cliniques ax\u00e9es sur les m\u00e9canismes inflammatoires.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00a0\u00bb1_2,1_2&Prime; custom_padding_last_edited=\u00a0\u00bbon|tablet\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_enable_image=\u00a0\u00bboff\u00a0\u00bb background_size=\u00a0\u00bbcontain\u00a0\u00bb background_blend=\u00a0\u00bbsoft-light\u00a0\u00bb max_width=\u00a0\u00bb80%\u00a0\u00bb custom_margin_tablet=\u00a0\u00bb0px||||false|false\u00a0\u00bb custom_margin_phone=\u00a0\u00bb0px||||false|false\u00a0\u00bb custom_margin_last_edited=\u00a0\u00bbon|tablet\u00a0\u00bb custom_padding_tablet=\u00a0\u00bb0px||||false|false\u00a0\u00bb custom_padding_phone=\u00a0\u00bb0px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb1_2&Prime; _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text admin_label=\u00a0\u00bbAtopic Dermatitis\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_text_color=\u00a0\u00bb#1F386B\u00a0\u00bb width=\u00a0\u00bb100%\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb custom_margin=\u00a0\u00bb|0px|||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb|0px|||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h2>Dermatite atopique<\/h2>\n<p>[\/et_pb_text][et_pb_text admin_label=\u00a0\u00bbDevonian has also completed&#8230;\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.5&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_text_color=\u00a0\u00bb#5ABCAD\u00a0\u00bb width=\u00a0\u00bb100%\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb custom_margin=\u00a0\u00bb|0px|||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb3px|0px|||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p>Devonian a achev\u00e9 une \u00e9tude clinique de phase II sur la dermatite atopique l\u00e9g\u00e8re \u00e0 mod\u00e9r\u00e9e, utilisant Thykamine<sup>MC<\/sup> sous forme de cr\u00e8me. L\u2019\u00e9tude de phase II \u00e9tait une \u00e9tude men\u00e9e \u00e0 double insu, \u00e0 r\u00e9partition al\u00e9atoire et contr\u00f4l\u00e9e par placebo, visant \u00e0 \u00e9valuer l\u2019efficacit\u00e9 et l\u2019innocuit\u00e9 de la cr\u00e8me Thykamine<sup>MC<\/sup> en monoth\u00e9rapie (0,05\u00a0%, 0,1\u00a0% et 0,25\u00a0%) comparativement au placebo, en ce qui concerne la clart\u00e9 de la peau, telle qu\u2019\u00e9valu\u00e9e par le score IGA (\u00c9valuation globale de l\u2019investigateur), chez des patients adultes atteints de dermatite atopique l\u00e9g\u00e8re \u00e0 mod\u00e9r\u00e9e. L\u2019efficacit\u00e9 et l\u2019innocuit\u00e9 ont \u00e9t\u00e9 \u00e9valu\u00e9es chaque semaine pendant une p\u00e9riode de traitement de quatre semaines, avec deux applications par jour. Un total de 162 patients, r\u00e9partis dans plusieurs centres au Canada, ont \u00e9t\u00e9 recrut\u00e9s pour cette \u00e9tude.<\/p>\n<p><\/p>\n<p>Comparativement au placebo, Thykamine<sup>MC<\/sup> \u00e0 0,1\u00a0% a d\u00e9montr\u00e9 une am\u00e9lioration significative du crit\u00e8re principal d\u2019\u00e9valuation, c\u2019est-\u00e0-dire la clart\u00e9 de la peau (IGA), \u00e0 toutes les \u00e9ch\u00e9ances mesur\u00e9es :<\/p>\n<p><\/p>\n<ul>\n<li>Semaine 1 : <em>p = 0,006<\/em><\/li>\n<li>Semaine 2 : <em>p &lt; 0,001<\/em><\/li>\n<li>Semaine 3 : <em>p &lt; 0,001<\/em><\/li>\n<li>Semaine 4 : <em>p = 0,002<\/em><\/li>\n<\/ul>\n<p><\/p>\n<p>Ces r\u00e9sultats d\u00e9montrent une apparition rapide de l\u2019effet th\u00e9rapeutique.<\/p>\n<p><\/p>\n<p>Les taux de r\u00e9ussite selon l\u2019IGA \u00e0 la semaine 4 \u00e9taient de :<\/p>\n<p><\/p>\n<ul>\n<li>6,7\u00a0% pour le placebo (cr\u00e8me v\u00e9hicule)<\/li>\n<li>19,0\u00a0% pour la cr\u00e8me Thykamine<sup>MC<\/sup> \u00e0 0,05\u00a0% (<em>p = 0,053<\/em> p\/r au placebo)<\/li>\n<li>30,8\u00a0% pour la cr\u00e8me Thykamine<sup>MC<\/sup> \u00e0 0,10\u00a0% (<em>p = 0,014<\/em> p\/r au placebo)<\/li>\n<li>12,1\u00a0% pour la cr\u00e8me Thykamine<sup>MC<\/sup> \u00e0 0,25\u00a0% (<em>p = 0,461<\/em> p\/r au placebo)<\/li>\n<\/ul>\n<p><\/p>\n<p>Le taux de r\u00e9ussite de la cr\u00e8me Thykamine<sup>MC<\/sup> 0,1\u00a0% comparativement au placebo a \u00e9t\u00e9 atteint non seulement \u00e0 la semaine 4, mais aussi \u00e0 la semaine 3 (<em>p = 0,04<\/em>), indiquant un d\u00e9but rapide de l\u2019effet th\u00e9rapeutique. Ainsi, la cr\u00e8me Thykamine<sup>MC<\/sup> \u00e0 0,10\u00a0% a \u00e9t\u00e9 retenue pour les essais de phase 3.<\/p>\n<p><\/p>\n<p>De plus, Thykamine<sup>MC <\/sup>a obtenu des diff\u00e9rences statistiquement significatives par rapport au placebo dans ses principaux crit\u00e8res secondaires d\u2019efficacit\u00e9, \u00e0 savoir la surface corporelle atteinte (SC), le prurit, le score POEM, et la qualit\u00e9 de vie.<\/p>\n<p><\/p>\n<p>Thykamine<sup>MC <\/sup>s\u2019est r\u00e9v\u00e9l\u00e9 s\u00fbr et bien tol\u00e9r\u00e9 pendant l\u2019\u00e9tude.<\/p>\n<p><\/p>\n<p>les k\u00e9ratinocytes, entra\u00eenant leur apoptose ainsi qu\u2019une chimiotaxie positive dans les vaisseaux sanguins\u2076.<\/p>\n<p><\/p>\n<p><strong>Stade de d\u00e9veloppement : <\/strong>Devonian d\u00e9veloppe actuellement une formulation sp\u00e9cifique dont le principal ingr\u00e9dient actif est Thykamine<sup>MC<\/sup>.<\/p>\n<p>[\/et_pb_text][et_pb_text admin_label=\u00a0\u00bbHand and Foot Syndrome Associatd to Chemotherapy\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_text_color=\u00a0\u00bb#1F386B\u00a0\u00bb width=\u00a0\u00bb100%\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb custom_margin=\u00a0\u00bb60px|0px|||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb|0px|||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h2>Maladie st\u00e9atosique h\u00e9patique associ\u00e9e \u00e0 une dysfonction m\u00e9tabolique (MASLD)<\/h2>\n<p>[\/et_pb_text][et_pb_text admin_label=\u00a0\u00bbHand-and-foot syndrome (HFS)&#8230;\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.5&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_text_color=\u00a0\u00bb#5ABCAD\u00a0\u00bb width=\u00a0\u00bb100%\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb custom_margin=\u00a0\u00bb|0px|||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb|0px|||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p>La maladie st\u00e9atosique h\u00e9patique associ\u00e9e \u00e0 une dysfonction m\u00e9tabolique (MASLD) regroupe un ensemble de troubles h\u00e9patiques caract\u00e9ris\u00e9s par une accumulation excessive de graisse dans le foie (st\u00e9atose h\u00e9patique), en pr\u00e9sence d\u2019au moins un facteur de risque cardiom\u00e9tabolique, tel que l\u2019ob\u00e9sit\u00e9, le diab\u00e8te de type 2, l\u2019hypertension art\u00e9rielle ou la dyslipid\u00e9mie. Elle inclut la st\u00e9atose simple, mais peut \u00e9voluer vers une st\u00e9ato-h\u00e9patite associ\u00e9e \u00e0 une dysfonction m\u00e9tabolique (MASH) \u2014 anciennement appel\u00e9e st\u00e9ato-h\u00e9patite non alcoolique (NASH) \u2014, la fibrose, la cirrhose et le carcinome h\u00e9patocellulaire (CHC).<\/p>\n<p><\/p>\n<p>Les crit\u00e8res histologiques de diagnostic de la MASH comprennent la st\u00e9atose, l\u2019inflammation lobulaire et les l\u00e9sions des h\u00e9patocytes (souvent sous forme de ballonisation cellulaire). Bien que la MASH puisse \u00eatre identifiable histologiquement, l\u2019absence de sympt\u00f4mes clairs et le manque de sensibilisation du public font qu\u2019il reste souvent non diagnostiqu\u00e9. Chez les adultes aux \u00c9tats-Unis, la pr\u00e9valence de la MASH \u00e9tait estim\u00e9e \u00e0 5,8\u00a0% en 2020 et devrait atteindre 7,9\u00a0% d\u2019ici 2050.<\/p>\n<p><\/p>\n<p>Une \u00e9tude a examin\u00e9 les effets de Thykamine<sup>MC<\/sup> sur la progression de la maladie h\u00e9patique dans le mod\u00e8le murin STAM, largement utilis\u00e9 pour \u00e9tudier la MASH et la fibrose. Dans ce mod\u00e8le, des souris diab\u00e9tiques recevant un r\u00e9gime riche en graisses d\u00e9veloppent rapidement une st\u00e9atose h\u00e9patique due \u00e0 l\u2019inflammation et \u00e0 l\u2019accumulation de lipides dans le foie. Resm\u00e9tirom, le premier m\u00e9dicament approuv\u00e9 par la FDA am\u00e9ricaine pour la prise en charge de la MASH, a \u00e9t\u00e9 utilis\u00e9 comme contr\u00f4le positif \u00e0 une dose orale de 3,0 mg\/kg une fois par jour pendant trois semaines.<\/p>\n<p><\/p>\n<p>Thykamine<sup>MC<\/sup>, administr\u00e9 par voie orale \u00e0 des doses de 0,5 mg\/kg, 5,0 mg\/kg et 50,0 mg\/kg une fois par jour pendant trois semaines, a montr\u00e9 un effet h\u00e9patoprotecteur, emp\u00eachant la progression de la maladie h\u00e9patique comparativement au groupe t\u00e9moin (v\u00e9hicule). Plus pr\u00e9cis\u00e9ment, le traitement par Thykamine<sup>MC<\/sup> a entra\u00een\u00e9 une r\u00e9duction significative du score d\u2019activit\u00e9 NAFLD (NAS), une mesure composite de la st\u00e9atose h\u00e9patique incluant la st\u00e9atose, l\u2019inflammation et la ballonisation des h\u00e9patocytes.<\/p>\n<p><\/p>\n<p>Le marqueur \u03b1-SMA, utilis\u00e9 pour \u00e9valuer la fibrose h\u00e9patique, a \u00e9galement \u00e9t\u00e9 significativement diminu\u00e9. Le traitement par Thykamine<sup>MC<\/sup> a r\u00e9duit l\u2019expression du collag\u00e8ne de type I, du collag\u00e8ne de type III, de F4\/F80, de Ly-6G, ainsi que du MARCO (r\u00e9cepteur macrophagique \u00e0 structure collag\u00e9nique). Les effets observ\u00e9s sur ces marqueurs \u00e9taient comparables \u00e0 ceux du Resm\u00e9tirom. Globalement, la progression de la fibrose h\u00e9patique a \u00e9t\u00e9 ralentie par le traitement au Thykamine<sup>MC<\/sup>.<\/p>\n<p><\/p>\n<p>Ces donn\u00e9es d\u00e9montrent une preuve de concept prometteuse des effets anti-inflammatoires et antifibrotiques du Thykamine<sup>MC<\/sup> dans la MASH.<\/p>\n<p><\/p>\n<p><strong>\u00c9tape de d\u00e9veloppement :<\/strong> Travaux pr\u00e9cliniques diff\u00e9renciants en cours<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00a0\u00bb1_2&Prime; _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text admin_label=\u00a0\u00bbUlcerative Colitis\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_text_color=\u00a0\u00bb#1F386B\u00a0\u00bb header_2_text_color=\u00a0\u00bb#1F386B\u00a0\u00bb width=\u00a0\u00bb100%\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb custom_margin=\u00a0\u00bb|0px|||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb|0px|||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h2>Colite ulc\u00e9reuse<\/h2>\n<p>[\/et_pb_text][et_pb_text admin_label=\u00a0\u00bbThe Corporation conducted&#8230;\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.5&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_text_color=\u00a0\u00bb#5ABCAD\u00a0\u00bb width=\u00a0\u00bb100%\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb custom_margin=\u00a0\u00bb|0px|||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb|0px|0px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p>La soci\u00e9t\u00e9 a men\u00e9 une \u00e9tude clinique de phase IIa en Allemagne. Il s\u2019agissait d\u2019une \u00e9tude exploratoire, \u00e0 r\u00e9partition al\u00e9atoire men\u00e9e \u00e0 double insu, avec groupes parall\u00e8les, \u00e0 doses multiples et contr\u00f4l\u00e9e par placebo, d\u2019une dur\u00e9e de deux semaines, visant \u00e0 \u00e9valuer l\u2019innocuit\u00e9 et la tol\u00e9rabilit\u00e9 de Thykamine<sup>MC<\/sup>, administr\u00e9 sous forme d\u2019\u00e9n\u00e8me rectal, chez des patients atteints de colite ulc\u00e9reuse active l\u00e9g\u00e8re \u00e0 mod\u00e9r\u00e9e. L\u2019efficacit\u00e9 a \u00e9galement \u00e9t\u00e9 \u00e9valu\u00e9e \u00e0 l\u2019aide du score de Mayo modifi\u00e9 et de divers biomarqueurs de l\u2019inflammation.<\/p>\n<p><\/p>\n<p>L\u2019objectif principal de l\u2019\u00e9tude a \u00e9t\u00e9 atteint. L\u2019administration quotidienne de doses de 250 mg, 500 mg et 1 000 mg de Thykamine<sup>MC<\/sup> sous forme d\u2019\u00e9n\u00e8me rectal s\u2019est r\u00e9v\u00e9l\u00e9e s\u00fbre et bien tol\u00e9r\u00e9e chez les sujets atteints de rectocolite ulc\u00e9reuse distale active l\u00e9g\u00e8re \u00e0 mod\u00e9r\u00e9e. Une r\u00e9duction statistiquement significative (p &lt; 0,05) du sous-score de saignement rectal du score de Mayo modifi\u00e9 \u2014 sympt\u00f4me cardinal de la maladie \u2014 a \u00e9t\u00e9 observ\u00e9e pour la dose de 250 mg de Thykamine<sup>MC <\/sup>comparativement au placebo \u00e0 la fin du traitement (jour 14).<\/p>\n<p><\/p>\n<p>Parmi les biomarqueurs \u00e9valu\u00e9s, on a observ\u00e9 des diminutions statistiquement significatives des taux de lactoferrine f\u00e9cale (LF) \u2014 biomarqueur hautement sp\u00e9cifique et sensible pour la d\u00e9tection de l\u2019inflammation intestinale \u2014 ainsi que du facteur de croissance transformant b\u00eata (TGF-\u03b2) et du complexe apoptosique s\u00e9rique M-30.<\/p>\n<p><\/p>\n<p>Ces r\u00e9sultats objectifs, fond\u00e9s sur les r\u00e9ductions de biomarqueurs et les \u00e9valuations cliniques, d\u00e9montrent l\u2019activit\u00e9 biologique de Thykamine<sup>MC <\/sup>administr\u00e9 par \u00e9n\u00e8me rectal chez les patients atteints de rectocolite ulc\u00e9reuse distale active l\u00e9g\u00e8re \u00e0 mod\u00e9r\u00e9e, et ce, apr\u00e8s une tr\u00e8s courte dur\u00e9e de traitement.<\/p>\n<p>[\/et_pb_text][et_pb_text admin_label=\u00a0\u00bbRadiodermatitis Associated to Radiotherapy\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_text_color=\u00a0\u00bb#1F386B\u00a0\u00bb width=\u00a0\u00bb100%\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb custom_margin=\u00a0\u00bb60px|0px|||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb|0px|||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h2>Radiodermite associ\u00e9e \u00e0 la radioth\u00e9rapie<\/h2>\n<p>[\/et_pb_text][et_pb_text admin_label=\u00a0\u00bbRadiodermatitis (radiation dermatitis)&#8230;\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.5&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_text_color=\u00a0\u00bb#5ABCAD\u00a0\u00bb width=\u00a0\u00bb100%\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb custom_margin=\u00a0\u00bb|0px|||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb|0px|0px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p>La radiodermite (ou dermatite radiologique) constitue un effet secondaire important de l\u2019exposition de la peau aux rayonnements ionisants utilis\u00e9s lors des traitements contre le cancer, ainsi que des attaques ou accidents nucl\u00e9aires.<\/p>\n<p><\/p>\n<p>La radiodermite est class\u00e9e en trois niveaux de gravit\u00e9 :<\/p>\n<p><\/p>\n<ul>\n<li>Grade 1 : \u00e9ryth\u00e8me l\u00e9ger<\/li>\n<li>Grade 2 : desquamation s\u00e8che<\/li>\n<li>Grade 3 : desquamation humide s\u00e9v\u00e8re<\/li>\n<\/ul>\n<p><\/p>\n<p>Les donn\u00e9es internationales indiquent que 50\u00a0% des patients atteints de cancer re\u00e7oivent une forme de radioth\u00e9rapie, et que la radiodermite touche environ 95\u00a0% d\u2019entre eux.<br \/>Elle est particuli\u00e8rement fr\u00e9quente dans les cancers du sein, du p\u00e9rin\u00e9e, ainsi que des r\u00e9gions de la t\u00eate et du cou.<\/p>\n<p><\/p>\n<p>Ces r\u00e9actions cutan\u00e9es li\u00e9es \u00e0 la radiation entra\u00eenent de nombreuses complications, notamment des retards ou interruptions de traitement, une alt\u00e9ration esth\u00e9tique et une diminution de la qualit\u00e9 de vie.<\/p>\n<p><\/p>\n<p><strong>Stade de d\u00e9veloppement: <\/strong>Devonian d\u00e9veloppe actuellement une formulation sp\u00e9cifique dont le principal ingr\u00e9dient actif est Thykamine<sup>MC<\/sup>.<\/p>\n<p>[\/et_pb_text][et_pb_image src=\u00a0\u00bbhttps:\/\/groupedevonian.com\/wp-content\/uploads\/2026\/05\/Page-produits-002.png\u00a0\u00bb title_text=\u00a0\u00bbPage-produits-(002)\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.6&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb hover_enabled=\u00a0\u00bb0&Prime; global_colors_info=\u00a0\u00bb{}\u00a0\u00bb sticky_enabled=\u00a0\u00bb0&Prime;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row custom_padding_last_edited=\u00a0\u00bbon|tablet\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_enable_image=\u00a0\u00bboff\u00a0\u00bb background_size=\u00a0\u00bbcontain\u00a0\u00bb background_blend=\u00a0\u00bbsoft-light\u00a0\u00bb max_width=\u00a0\u00bb80%\u00a0\u00bb custom_margin_tablet=\u00a0\u00bb0px||||false|false\u00a0\u00bb custom_margin_phone=\u00a0\u00bb0px||||false|false\u00a0\u00bb custom_margin_last_edited=\u00a0\u00bbon|tablet\u00a0\u00bb custom_padding_tablet=\u00a0\u00bb0px||||false|false\u00a0\u00bb custom_padding_phone=\u00a0\u00bb0px||||false|false\u00a0\u00bb hover_enabled=\u00a0\u00bb0&Prime; global_colors_info=\u00a0\u00bb{}\u00a0\u00bb sticky_enabled=\u00a0\u00bb0&Prime;][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text admin_label=\u00a0\u00bbHand and Foot Syndrome Associatd to Chemotherapy\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.6&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_text_color=\u00a0\u00bb#1F386B\u00a0\u00bb width=\u00a0\u00bb100%\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb custom_padding=\u00a0\u00bb|0px|||false|false\u00a0\u00bb hover_enabled=\u00a0\u00bb0&Prime; global_colors_info=\u00a0\u00bb{}\u00a0\u00bb sticky_enabled=\u00a0\u00bb0&Prime;]<\/p>\n<h2>\u0152sophagite \u00e0 \u00e9osinophiles<\/h2>\n<p>[\/et_pb_text][et_pb_text admin_label=\u00a0\u00bbHand-and-foot syndrome (HFS)&#8230;\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.5&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_text_color=\u00a0\u00bb#5ABCAD\u00a0\u00bb width=\u00a0\u00bb100%\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb custom_margin=\u00a0\u00bb|0px|||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb|0px|||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p>Le syndrome main-pied (SMP), \u00e9galement appel\u00e9 \u00e9rythrodysesth\u00e9sie palmo-plantaire ou \u00e9ryth\u00e8me acral, est un effet ind\u00e9sirable bien document\u00e9 de nombreux agents chimioth\u00e9rapeutiques<sup>1,2,3,4,5<\/sup>. Les manifestations cliniques les plus courantes comprennent un \u00e9ryth\u00e8me, une dysesth\u00e9sie, des douleurs, des fissures et une desquamation.<\/p>\n<p><\/p>\n<p>Les principales mol\u00e9cules en cause sont la doxorubicine liposomale p\u00e9gyl\u00e9e (PLD), la cap\u00e9citabine, le 5-fluorouracile (5-FU), la cytarabine et le doc\u00e9taxel. De plus, certains inhibiteurs multikinases cibl\u00e9s (IMK) de nouvelle g\u00e9n\u00e9ration, tels que le soraf\u00e9nib, le sunif\u00e9nib, l\u2019axitinib, le pazopanib, le r\u00e9goraf\u00e9nib et le v\u00e9muraf\u00e9nib, peuvent \u00e9galement provoquer des r\u00e9actions au niveau des mains et des pieds.<\/p>\n<p><\/p>\n<p>L\u2019incidence du SMP varie selon l\u2019agent causal :<\/p>\n<p><\/p>\n<ul>\n<li>La PLD et la cap\u00e9citabine pr\u00e9sentent les taux les plus \u00e9lev\u00e9s, atteignant 40 \u00e0 50\u00a0% et 50 \u00e0 60\u00a0%, respectivement.<\/li>\n<li>Les IMK, tels que le soraf\u00e9nib et le sunif\u00e9nib, provoquent un SMP chez 10 \u00e0 28\u00a0% et 10 \u00e0 62\u00a0% des patients, respectivement.<\/li>\n<\/ul>\n<p><\/p>\n<p>&nbsp;<\/p>\n<p><\/p>\n<p>Certaines combinaisons chimioth\u00e9rapeutiques peuvent \u00e9galement augmenter le risque de survenue du syndrome. Le risque de SMP est dose-d\u00e9pendant : les formulations qui prolongent la concentration s\u00e9rique du m\u00e9dicament ou favorisent son accumulation dans les zones touch\u00e9es entra\u00eenent des taux plus \u00e9lev\u00e9s. En g\u00e9n\u00e9ral, l\u2019arr\u00eat ou la r\u00e9duction de la dose du m\u00e9dicament en cause permet une am\u00e9lioration des sympt\u00f4mes.<\/p>\n<p><\/p>\n<p>La pathog\u00e9nie du SMP demeure mal comprise. Il a \u00e9t\u00e9 sugg\u00e9r\u00e9 que la pr\u00e9dilection du syndrome pour les paumes et les plantes des pieds pourrait r\u00e9sulter d\u2019une accumulation du m\u00e9dicament dans les canaux eccrines de ces r\u00e9gions\u00b2\u2075. L\u2019inflammation et l\u2019apoptose m\u00e9di\u00e9es par les esp\u00e8ces r\u00e9actives de l\u2019oxyg\u00e8ne (ROS) constituent un facteur cl\u00e9 dans le d\u00e9veloppement du syndrome<sup>6,7,8<\/sup>. Ces ROS induisent la lib\u00e9ration de chimiokines et de cytokines inflammatoires par les k\u00e9ratinocytes, entra\u00eenant leur apoptose ainsi qu\u2019une chimiotaxie positive dans les vaisseaux sanguins\u2076.<\/p>\n<p><\/p>\n<p><strong>Stade de d\u00e9veloppement: <\/strong>Devonian d\u00e9veloppe actuellement une formulation sp\u00e9cifique dont le principal ingr\u00e9dient actif est Thykamine<sup>MC<\/sup>.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1&Prime; _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_color=\u00a0\u00bb#f4f4f4&Prime; custom_padding=\u00a0\u00bb102px||80px||false|false\u00a0\u00bb top_divider_color=\u00a0\u00bb#1B303B\u00a0\u00bb top_divider_height=\u00a0\u00bb50px\u00a0\u00bb bottom_divider_color=\u00a0\u00bb#1B303B\u00a0\u00bb bottom_divider_height=\u00a0\u00bb50px\u00a0\u00bb bottom_divider_flip=\u00a0\u00bbhorizontal\u00a0\u00bb custom_css_main_element=\u00a0\u00bbbackground: url(\/wp-content\/uploads\/2025\/11\/dots-br.png)\/*, url(\/wp-content\/uploads\/2025\/11\/lines-bl.png)*\/, url(\/wp-content\/uploads\/2025\/11\/dots-tl.png)\/*, url(\/wp-content\/uploads\/2025\/11\/lueur-bl-v2.png)*\/ !important;||background-repeat: no-repeat !important;||background-position: right bottom,\/* left bottom,*\/ left top\/*, left bottom*\/  !important;||background-size: auto !important;\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb custom_css_main_element_last_edited=\u00a0\u00bbon|desktop\u00a0\u00bb custom_css_main_element_tablet=\u00a0\u00bbbackground: url(\/wp-content\/uploads\/2025\/11\/dots-br.png)\/*, url(\/wp-content\/uploads\/2025\/11\/lines-bl.png)*\/, url(\/wp-content\/uploads\/2025\/12\/dot-top-right.png)\/*, url(\/wp-content\/uploads\/2025\/11\/lueur-bl-v2.png)*\/ !important;||background-repeat: no-repeat !important;||background-position: right bottom\/*, left bottom*\/, right top\/*, left bottom *\/ !important;||background-size: auto !important;\u00a0\u00bb custom_css_main_element_phone=\u00a0\u00bbbackground: url(\/wp-content\/uploads\/2025\/11\/dots-br.png)\/*, url(\/wp-content\/uploads\/2025\/11\/lines-bl.png)*\/, url(\/wp-content\/uploads\/2025\/12\/dot-top-right.png)\/*, url(\/wp-content\/uploads\/2025\/11\/lueur-bl-v2.png)*\/ !important;||background-repeat: no-repeat !important;||background-position: right bottom\/*, left bottom*\/, right top\/*, left bottom *\/ !important;||background-size: auto !important;\u00a0\u00bb][et_pb_row custom_padding_last_edited=\u00a0\u00bbon|tablet\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_enable_image=\u00a0\u00bboff\u00a0\u00bb background_size=\u00a0\u00bbcontain\u00a0\u00bb background_blend=\u00a0\u00bbsoft-light\u00a0\u00bb max_width=\u00a0\u00bb80%\u00a0\u00bb custom_margin_tablet=\u00a0\u00bb0px||||false|false\u00a0\u00bb custom_margin_phone=\u00a0\u00bb0px||||false|false\u00a0\u00bb custom_margin_last_edited=\u00a0\u00bbon|tablet\u00a0\u00bb custom_padding_tablet=\u00a0\u00bb0px||||false|false\u00a0\u00bb custom_padding_phone=\u00a0\u00bb0px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text admin_label=\u00a0\u00bbReferences\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_text_color=\u00a0\u00bb#1F386B\u00a0\u00bb width=\u00a0\u00bb100%\u00a0\u00bb max_width=\u00a0\u00bb100%\u00a0\u00bb custom_margin=\u00a0\u00bb|0px|||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb|0px|||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h2>R\u00e9f\u00e9rences<\/h2>\n<p><\/p>\n<ol>\n<li>Singh M., Alavi A., Wong R., Akita S. Radiodermatitis: A Review of Our Current Understanding. Am J Clin Dermatol 17:277\u2013292, 2016.<br \/>Link: <a href=\"https:\/\/link.springer.com\/article\/10.1007\/s40257-016-0186-4\" target=\"_blank\" rel=\"noopener\">https:\/\/link.springer.com\/article\/10.1007\/s40257-016-0186-4<\/a><\/li>\n<li>Charles Lynde, Yves Poulin, Jerry Tan, Mark Lomaga, Wei-Jing Loo, Diane Carbonneau, Isabelle Delorme, Doria Grimard, John Sampalis. Phase 2 Trial of Topical Thykamine in Adults With Mild to Moderate Atopic Dermatitis. J Drugs Dermatol 2022 Oct 1;21(10):1091-1097.<br \/>Link: <a href=\"https:\/\/jddonline.com\/articles\/phase-2-trial-of-topical-thykamine-in-adults-with-mild-to-moderate-atopic-dermatitis-S1545961622P1091X\/\" target=\"_blank\" rel=\"noopener\">https:\/\/jddonline.com\/articles\/phase-2-trial-of-topical-thykamine-in-adults-with-mild-to-moderate-atopic-dermatitis-S1545961622P1091X\/<\/a><\/li>\n<li>Mej\u00eda-Guzm\u00e1n JE, Belmont-Hern\u00e1ndez RA, Ch\u00e1vez-Tapia NC, Uribe M, Nu\u00f1o-L\u00e1mbarri N. Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies. International Journal of Molecular Sciences 2025; 26(7): 2959.<br \/>Link: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40243565\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/40243565\/<\/a><\/li>\n<li>van Son KC, Te Nijenhuis-Noort LC, Boone SC, Mook-Kanamori DO, Holleboom AG, Roos PR, Lamb HJ, Alblas G, Coenraad MJ, Rosendaal FR, de Mutsert R, Tushuizen ME. Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies. Medicine (Baltimore). 2024 Jan 5;103(1):e34934. doi: 10.1097\/MD.0000000000034934. <br \/>Link: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38181294\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/38181294\/\u00a0<\/a><\/li>\n<li>Hardy T, Oakley F, Anstee QM, Day CP. Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. Annu Rev Pathol. 2016 May 23;11:451-96. doi: 10.1146\/annurev-pathol-012615-044224. Epub 2016 Mar 3. PMID: 26980160. <br \/>Link: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26980160\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/26980160\/<\/a><\/li>\n<li>Eskridge W, Cryer DR, Schattenberg JM, Gastaldelli A, Malhi H, Allen AM, Noureddin M, Sanyal AJ. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective. J Clin Med. 2023 Sep 26;12(19):6216. doi: 10.3390\/jcm12196216. <br \/>Link: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37834859\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/37834859\/<\/a><\/li>\n<li>Le P, Tatar M, Dasarathy S, Alkhouri N, Herman WH, Taksler GB, Deshpande A, Ye W, Adekunle OA, McCullough A, Rothberg MB. Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050. JAMA Netw Open. 2025 Jan 2;8(1):e2454707. doi: 10.1001\/jamanetworkopen.2024.54707.<br \/>Lien : <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39821400\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/39821400\/<\/a><\/li>\n<li>In Vivo Efficacy Study of Thykamine in STAM\u2122 Model of Metabolic dysfunction-associated steatohepatitis. January 17, 2025, Study Report on file at Devonian Health Group Inc. <br \/>Link : <a href=\"https:\/\/groupedevonian.com\/devonian-reports-positive-results-in-mash-liver-study\/\">https:\/\/groupedevonian.com\/devonian-reports-positive-results-in-mash-liver-study\/<\/a><\/li>\n<li>Furuta GT, Katzka DA. Eosinophilic Esophagitis. N Engl J Med. 2015 Oct 22;373(17):1640-8. doi: 10.1056\/NEJMra1502863. <br \/>Link : <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26488694\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/26488694\/<\/a><\/li>\n<li>Muir A, Falk GW. Eosinophilic Esophagitis: A Review. JAMA. 2021 Oct 5;326(13):1310-1318. doi: 10.1001\/jama.2021.14920. <br \/>Link : <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34609446\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/34609446\/<\/a><\/li>\n<li>Dellon ES, Hirano I. Epidemiology and Natural History of Eosinophilic Esophagitis. Gastroenterology. 2018 Jan;154(2):319-332.e3. doi: 10.1053\/j.gastro.2017.06.067. Epub 2017 Aug 1. PMID: 28774845; <br \/>Link : <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28774845\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/28774845\/<\/a><\/li>\n<li>Navarro P, Arias \u00c1, Arias-Gonz\u00e1lez L, Laserna-Mendieta EJ, Ruiz-Ponce M, Lucendo AJ. Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment Pharmacol Ther. 2019 May;49(9):1116-1125. doi: 10.1111\/apt.15231. Epub 2019 Mar 18.\u00a0<br \/>Link: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30887555\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/30887555\/<\/a><\/li>\n<li>Dellon ES, Erichsen R, Baron JA, Shaheen NJ, Vyberg M, Sorensen HT, Pedersen L. The increasing incidence and prevalence of eosinophilic oesophagitis outpaces changes in endoscopic and biopsy practice: national population-based estimates from Denmark. Aliment Pharmacol Ther. 2015 Apr;41(7):662-70. doi: 10.1111\/apt.13129. Epub 2015 Feb 12. <br \/>Link: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25684441\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/25684441\/<\/a><\/li>\n<li>Warners MJ, de Rooij W, van Rhijn BD, Verheij J, Bruggink AH, Smout AJPM, Bredenoord AJ. Incidence of eosinophilic esophagitis in the Netherlands continues to rise: 20-year results from a nationwide pathology database. Neurogastroenterol Motil. 2018 Jan;30(1). doi: 10.1111\/nmo.13165. Epub 2017 Jul 26.\u00a0<br \/>Link: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28745828\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/28745828\/<\/a><\/li>\n<\/ol>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1&Prime; custom_padding_last_edited=\u00a0\u00bbon|phone\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_image=\u00a0\u00bbhttps:\/\/groupedevonian.com\/wp-content\/uploads\/2025\/11\/cta-targeted.png\u00a0\u00bb custom_padding=\u00a0\u00bb174px||174px||true|\u00a0\u00bb custom_padding_tablet=\u00a0\u00bb174px||174px||true|\u00a0\u00bb custom_padding_phone=\u00a0\u00bb|24px||24px|true|true\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb width=\u00a0\u00bb90%\u00a0\u00bb max_width=\u00a0\u00bb90%\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text admin_label=\u00a0\u00bbTargeted Therapies\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb header_2_font_size=\u00a0\u00bb38px\u00a0\u00bb header_3_text_align=\u00a0\u00bbcenter\u00a0\u00bb header_3_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb header_3_font_size=\u00a0\u00bb30px\u00a0\u00bb text_orientation=\u00a0\u00bbcenter\u00a0\u00bb max_width=\u00a0\u00bb1080px\u00a0\u00bb module_alignment=\u00a0\u00bbcenter\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h3>Th\u00e9rapie cibl\u00e9e<\/h3>\n<p>[\/et_pb_text][et_pb_button button_url=\u00a0\u00bb@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9saW5rX3VybF9wYWdlIiwic2V0dGluZ3MiOnsicG9zdF9pZCI6IjEyNjIifX0=@\u00a0\u00bb button_text=\u00a0\u00bbEn savoir plus\u00a0\u00bb button_alignment=\u00a0\u00bbcenter\u00a0\u00bb admin_label=\u00a0\u00bbButton &#8211; Learn more\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _dynamic_attributes=\u00a0\u00bbbutton_url\u00a0\u00bb _module_preset=\u00a0\u00bbdefault\u00a0\u00bb filter_saturate=\u00a0\u00bb-190%\u00a0\u00bb filter_brightness=\u00a0\u00bb-130%\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1&Prime; custom_padding_last_edited=\u00a0\u00bbon|phone\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb custom_padding=\u00a0\u00bb180px||240px||false|false\u00a0\u00bb custom_padding_tablet=\u00a0\u00bb120px||120px||false|false\u00a0\u00bb custom_padding_phone=\u00a0\u00bb||||false|false\u00a0\u00bb top_divider_color=\u00a0\u00bb#1F376D\u00a0\u00bb top_divider_flip=\u00a0\u00bbhorizontal\u00a0\u00bb bottom_divider_style=\u00a0\u00bbwave\u00a0\u00bb bottom_divider_color=\u00a0\u00bb#1F386B\u00a0\u00bb bottom_divider_height=\u00a0\u00bb50px\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row _builder_version=\u00a0\u00bb4.17.3&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.16&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text admin_label=\u00a0\u00bbDevonian\u2019s technology&#8230;\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_3_text_align=\u00a0\u00bbcenter\u00a0\u00bb header_3_text_color=\u00a0\u00bb#1F386B\u00a0\u00bb header_3_line_height=\u00a0\u00bb1.2em\u00a0\u00bb background_enable_color=\u00a0\u00bboff\u00a0\u00bb text_orientation=\u00a0\u00bbcenter\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h3>La technologie de Devonian repose sur une plateforme scientifique \u00e9tendue, issue de plus de quinze ann\u00e9es de recherche.<\/h3>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Produits th\u00e9rapeutiquesThykamineMCThykamineMC\u00a0constitue un candidat-m\u00e9dicament de premier plan dont les profils d\u2019innocuit\u00e9 et d\u2019efficacit\u00e9 ont \u00e9t\u00e9 d\u00e9montr\u00e9s dans de nombreuses \u00e9tudes pr\u00e9cliniques et cliniques ax\u00e9es sur les m\u00e9canismes inflammatoires.Dermatite atopiqueDevonian a achev\u00e9 une \u00e9tude clinique de phase II sur la dermatite atopique l\u00e9g\u00e8re \u00e0 mod\u00e9r\u00e9e, utilisant ThykamineMC sous forme de cr\u00e8me. L\u2019\u00e9tude de phase II \u00e9tait [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":2201,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-1768","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Produits th\u00e9rapeutiques - DEVONIAN HEALTH GROUP INC.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/groupedevonian.com\/fr\/produits\/therapeutic\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Produits th\u00e9rapeutiques - DEVONIAN HEALTH GROUP INC.\" \/>\n<meta property=\"og:description\" content=\"Produits th\u00e9rapeutiquesThykamineMCThykamineMC\u00a0constitue un candidat-m\u00e9dicament de premier plan dont les profils d\u2019innocuit\u00e9 et d\u2019efficacit\u00e9 ont \u00e9t\u00e9 d\u00e9montr\u00e9s dans de nombreuses \u00e9tudes pr\u00e9cliniques et cliniques ax\u00e9es sur les m\u00e9canismes inflammatoires.Dermatite atopiqueDevonian a achev\u00e9 une \u00e9tude clinique de phase II sur la dermatite atopique l\u00e9g\u00e8re \u00e0 mod\u00e9r\u00e9e, utilisant ThykamineMC sous forme de cr\u00e8me. L\u2019\u00e9tude de phase II \u00e9tait [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/groupedevonian.com\/fr\/produits\/therapeutic\/\" \/>\n<meta property=\"og:site_name\" content=\"DEVONIAN HEALTH GROUP INC.\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-14T14:01:59+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/produits\\\/therapeutic\\\/\",\"url\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/produits\\\/therapeutic\\\/\",\"name\":\"Produits th\u00e9rapeutiques - DEVONIAN HEALTH GROUP INC.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/#website\"},\"datePublished\":\"2016-06-29T20:04:44+00:00\",\"dateModified\":\"2026-05-14T14:01:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/produits\\\/therapeutic\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/produits\\\/therapeutic\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/produits\\\/therapeutic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Produits\",\"item\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/products\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Produits th\u00e9rapeutiques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/\",\"name\":\"DEVONIAN HEALTH GROUP INC.\",\"description\":\"Botanical pharmaceutical corporation\",\"publisher\":{\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/#organization\",\"name\":\"Groupe Sant\u00e9 Devonian inc.\",\"alternateName\":\"Groupe Sant\u00e9 Devonian inc.\",\"url\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/groupedevonian.com\\\/wp-content\\\/uploads\\\/2022\\\/05\\\/logo-devonian-2x.png\",\"contentUrl\":\"https:\\\/\\\/groupedevonian.com\\\/wp-content\\\/uploads\\\/2022\\\/05\\\/logo-devonian-2x.png\",\"width\":309,\"height\":183,\"caption\":\"Groupe Sant\u00e9 Devonian inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/groupedevonian.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Produits th\u00e9rapeutiques - DEVONIAN HEALTH GROUP INC.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/groupedevonian.com\/fr\/produits\/therapeutic\/","og_locale":"fr_FR","og_type":"article","og_title":"Produits th\u00e9rapeutiques - DEVONIAN HEALTH GROUP INC.","og_description":"Produits th\u00e9rapeutiquesThykamineMCThykamineMC\u00a0constitue un candidat-m\u00e9dicament de premier plan dont les profils d\u2019innocuit\u00e9 et d\u2019efficacit\u00e9 ont \u00e9t\u00e9 d\u00e9montr\u00e9s dans de nombreuses \u00e9tudes pr\u00e9cliniques et cliniques ax\u00e9es sur les m\u00e9canismes inflammatoires.Dermatite atopiqueDevonian a achev\u00e9 une \u00e9tude clinique de phase II sur la dermatite atopique l\u00e9g\u00e8re \u00e0 mod\u00e9r\u00e9e, utilisant ThykamineMC sous forme de cr\u00e8me. L\u2019\u00e9tude de phase II \u00e9tait [&hellip;]","og_url":"https:\/\/groupedevonian.com\/fr\/produits\/therapeutic\/","og_site_name":"DEVONIAN HEALTH GROUP INC.","article_modified_time":"2026-05-14T14:01:59+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/groupedevonian.com\/fr\/produits\/therapeutic\/","url":"https:\/\/groupedevonian.com\/fr\/produits\/therapeutic\/","name":"Produits th\u00e9rapeutiques - DEVONIAN HEALTH GROUP INC.","isPartOf":{"@id":"https:\/\/groupedevonian.com\/fr\/#website"},"datePublished":"2016-06-29T20:04:44+00:00","dateModified":"2026-05-14T14:01:59+00:00","breadcrumb":{"@id":"https:\/\/groupedevonian.com\/fr\/produits\/therapeutic\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/groupedevonian.com\/fr\/produits\/therapeutic\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/groupedevonian.com\/fr\/produits\/therapeutic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/groupedevonian.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Produits","item":"https:\/\/groupedevonian.com\/fr\/products\/"},{"@type":"ListItem","position":3,"name":"Produits th\u00e9rapeutiques"}]},{"@type":"WebSite","@id":"https:\/\/groupedevonian.com\/fr\/#website","url":"https:\/\/groupedevonian.com\/fr\/","name":"DEVONIAN HEALTH GROUP INC.","description":"Botanical pharmaceutical corporation","publisher":{"@id":"https:\/\/groupedevonian.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/groupedevonian.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/groupedevonian.com\/fr\/#organization","name":"Groupe Sant\u00e9 Devonian inc.","alternateName":"Groupe Sant\u00e9 Devonian inc.","url":"https:\/\/groupedevonian.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/groupedevonian.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/groupedevonian.com\/wp-content\/uploads\/2022\/05\/logo-devonian-2x.png","contentUrl":"https:\/\/groupedevonian.com\/wp-content\/uploads\/2022\/05\/logo-devonian-2x.png","width":309,"height":183,"caption":"Groupe Sant\u00e9 Devonian inc."},"image":{"@id":"https:\/\/groupedevonian.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/pages\/1768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/comments?post=1768"}],"version-history":[{"count":7,"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/pages\/1768\/revisions"}],"predecessor-version":[{"id":13944,"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/pages\/1768\/revisions\/13944"}],"up":[{"embeddable":true,"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/pages\/2201"}],"wp:attachment":[{"href":"https:\/\/groupedevonian.com\/fr\/wp-json\/wp\/v2\/media?parent=1768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}